Company news

SAB Biotherapeutics, Inc. news in 2024

SAB Biotherapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

November 5, 2024

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

October 30, 2024

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

September 12, 2024

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

September 8, 2024

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

September 3, 2024

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

August 7, 2024

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

August 4, 2024

SAB BIO Appoints Lucy To as Chief Financial Officer

July 30, 2024

SAb Biotherapeutics Rebrands as SAB BIO

June 19, 2024

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

June 17, 2024

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 29, 2024

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 19, 2024

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

May 5, 2024

SAB Biotherapeutics Provides SAB-142 Trial Update

April 15, 2024

SAB Biotherapeutics to Present at INNODIA Annual Meeting

April 7, 2024

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

April 3, 2024

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

March 28, 2024

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

March 24, 2024

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

February 22, 2024

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 7, 2024

SAB Biotherapeutics Announces Executive Leadership Change

February 1, 2024

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

January 22, 2024

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

January 1, 2024

Decks in 2024